Botulinum toxin type A + Botulinum toxin type A + Placebo + Placebo
Phase 3Completed 0 views this week 0 watching💤 Quiet
Interest: 37/100
37
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Glabellar Lines
Conditions
Glabellar Lines
Trial Timeline
Apr 1, 2015 → Sep 6, 2017
NCT ID
NCT02450526About Botulinum toxin type A + Botulinum toxin type A + Placebo + Placebo
Botulinum toxin type A + Botulinum toxin type A + Placebo + Placebo is a phase 3 stage product being developed by Ipsen for Glabellar Lines. The current trial status is completed. This product is registered under clinical trial identifier NCT02450526. Target conditions include Glabellar Lines.
What happened to similar drugs?
0 of 10 similar drugs in Glabellar Lines were approved
Approved (0) Terminated (0) Active (10)
Hype Score Breakdown
Clinical
17
Activity
8
Company
12
Novelty
0
Community
0
Clinical Trials (3)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02660359 | Phase 3 | Terminated |
| NCT02660138 | Phase 3 | Terminated |
| NCT02450526 | Phase 3 | Completed |
Competing Products
19 competing products in Glabellar Lines
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| AGN-151586 + BOTOX + Placebo | AbbVie | Phase 1 | 29 |
| Placebo + AGN-151586 | AbbVie | Phase 3 | 40 |
| AGN-151586 + Placebo | AbbVie | Phase 3 | 40 |
| AGN-151586 + OnabotulinumtoxinA + Placebo | AbbVie | Phase 1 | 29 |
| AGN-151586 + Placebo | AbbVie | Phase 3 | 40 |
| AGN-151586 | AbbVie | Phase 3 | 40 |
| AGN-151586 + Placebo | AbbVie | Phase 1 | 29 |
| IPN10200 + Placebo | Ipsen | Phase 3 | 44 |
| Botulinum toxin type A + Placebo | Ipsen | Phase 3 | 37 |
| Botulinum toxin type A + Botulinum toxin type A + Placebo | Ipsen | Phase 2 | 32 |
| Botulinum toxin type A + Placebo | Ipsen | Phase 3 | 37 |
| IPN10200 + Placebo | Ipsen | Phase 3 | 44 |
| prabotulinumtoxinA | Evolus | Pre-clinical | 20 |
| PrabotulinumtoxinA-Xvfs + OnabotulinumtoxinA + PrabotulinumtoxinA-Xvfs | Evolus | Phase 2 | 25 |
| Botulinum toxin, Type A | Evolus | Phase 3 | 30 |
| DWP-450 (Botulinum purified neurotoxin, Type A) | Evolus | Phase 2 | 25 |
| Botulinum toxin, Type A | Evolus | Phase 3 | 30 |
| Botulinum purified neurotoxin, Type A | Evolus | Phase 2 | 25 |
| prabotulinumtoxinA | Evolus | Phase 1 | 19 |